Iovance Biotherapeutics shares rise 3.27% intraday as private investment in oncology ventures surges.

Iovance Biotherapeutics, Inc. rose 3.27% during intraday trading. The surge in stock price can be attributed to the recent news that private investment is helping to fill the gap in cancer research efforts in the United States, with oncology ventures securing hundreds of millions in funding so far in 2025. Investors are focusing on companies with standout science, solid pipelines, and clear regulatory strategies, including Iovance Biotherapeutics.